MedTrace Logo

MAQ-001 in Patients With Advanced Solid Tumors

NCT06514651 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-23

No results posted yet for this study

Summary

The goal of this interventional study is to test a new monoclonal antibody, called MAQ-001, as a potential treatment for certain types of advanced cancers in different organs or compartments, such as skin, lung, kidney, liver, stomach, bowel, the female reproductive system, and hematology lymph node cancers. The main question\[s\] it aims to answer are:

* the best dose of MAQ-001 that is safe to use alone or in combination with another anti-cancer medicine ipilimumab;
* how MAQ-001 works in the body and how it affects the whole cancer and its cells.

Participants will:

* receive a defined dose of MAQ-001 or MAQ-001 in combination with ipilimumab (depending on rank of enrolment) on day 1 of a 21-day cycle, for a maximum of 2 years.
* receive safety examinations and tumor assessment
* donate blood and other biological materials for safety and pharmacokinetic evaluation

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

MAQ-001

MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade

DRUG

Ipilimumab

Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system

Sponsors & Collaborators

  • MabQuest SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-06
Primary Completion
2026-06-30
Completion
2028-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514651 on ClinicalTrials.gov